Current Issue Volume 10, Number 1 , January-April 2018

FROM THE DESK OF EDITOR-IN-CHIEF
Amit Agarwal

From the Desk of Editor-in-Chief

[Year:2018] [Month:January-April] [Volumn:10 ] [Number:1] [Pages:97] [Pages No:iv]



I am delighted to share with all the members and office bearers of AsAES, the special issue of WJOES with the abstracts of “16th Biennial Congress of Asian Association of Endocrine Surgeons”. This is the third special issue after the publication of abstracts of two previous meetings held in Sri Lanka in 2014 and South Korea in 2016.


ORIGINAL ARTICLE
Roma Pradhan, Sushil Gupta, Niraj Kumari, Amit Agarwal

Adrenocorticotropic Hormone-producing Neuroendocrine Tumors of Thymus: Case Series and Review of Literature

[Year:2018] [Month:January-April] [Volumn:10 ] [Number:1] [Pages:97] [Pages No:1-4]



Since the first description of thymic carcinoid as a specific entity in 1972 by Rosai and Higa, approximately 92 cases of adrenocorticotropic hormone (ACTH)-producing thymic neuroendocrine associated with Cushing’s syndrome (CS) have been described between 1980 and 2011. We report here three new cases of neuroendocrine tumor (NET) of thymus associated with ectopic production of ACTH along with review of recent literature.
All our three cases were middle age (2 male and 1 female) with clinical features of CS. Two of the three patients had hyperpigmentation. All the three underwent transsternal excision of thymic tumor.
The NET of the thymus associated with CS can occur at any age from 4 to 64 years; however, meta-analysis revealed that majority of cases occur between 18 and 40 years. There is no sex predilection for these tumors except for the NETs which are associated with MEN-1, which occurred predominantly in males.
Majority of these patients would present with clinical features of CS, although the severity and rapidity of onset would vary.
The ACTH-producing NET is a rare cause of CS and requires high suspicion to make an early diagnosis and is a locally aggressive disease that requires aggressive surgical resection. Adjuvant radiotherapy may be beneficial.

Keywords: Adrenocorticotropic hormone, Cushing’s syndrome, Neuroendocrine tumors.

How to cite this article: Pradhan R, Gupta S, Kumari N, Agarwal A. Adrenocorticotropic Hormone-producing Neuroendocrine Tumors of Thymus: Case Series and Review of Literature. World J Endoc Surg 2018;10(1):1-4.

Source of support: Nil

Conflict of interest: None


CASE REPORT
Angeliki Chorti, Ioannis Pliakos, Stavros Panidis, Triantafyllia Koletsa, Tzikos Georgios, Mouslech Zadala, Christina Manani, Antonios Michalopoulos, Theodossis S Papavramidis

Parathyroid Cyst containing an Adenoma: A Rare Cervical Lesion causing Hyperparathyroidism

[Year:2018] [Month:January-April] [Volumn:10 ] [Number:1] [Pages:97] [Pages No:5-7]



Aim and introduction: Parathyroid cysts (PCs) are lesions arising from the parathyroid glands and are located from the angle of the mandible to the mediastinum, representing 1 to 5% of neck masses. They have a female predominance and occur usually in the fourth and fifth decade of life. They are subdivided into two categories according to their hormonal activity: Functioning and nonfunctioning ones. Except for parathyroid adenoma, hyperplasia, and carcinoma, functioning cysts are an additional rare cause of primary hyperparathyroidism (PH) and should be taken into consideration in the investigation of cystic neck masses.

Case report: We report a case of 38-year-old man, who was admitted to our hospital for the investigation of an asymptomatic hypercalcemia identified incidentally. In his laboratory tests, ionized calcium and parathormone (PTH) were elevated, while phosphorus was decreased. A 6.5 × 3.5 cm cystic structure was revealed in ultrasound examination, scintigraphy, and magnetic resonance imaging (MRI) scan, but was not indicative of PC, and surgical exploration was mandatory. The cyst was completely excised and the pathological examination revealed a PC that coexisted with an adenoma. Postoperative PTH, calcium, and phosphorus values were within normal ranges and the patient was discharged the first postoperative day.

Conclusion and clinical significance: Parathyroid cysts should be treated with gentle manipulations during surgical procedure in order that it is not ruptured and the recurrence is avoided.

Keywords: Hyperparathyroidism, Parathyroid adenoma, Parathyroid cyst, Parathyroid glands.

How to cite this article: Chorti A, Pliakos I, Panidis S, Koletsa T, Georgios K, Zadala M, Manani C, Michalopoulos A, Papavramidis TS. Parathyroid Cyst containing an Adenoma: A Rare Cervical Lesion causing Hyperparathyroidism. World J Endoc Surg 2018;10(1):5-7.

Source of support: Nil

Conflict of interest: None


ABSTRACT

Oral Presentations

[Year:2018] [Month:January-April] [Volumn:10 ] [Number:1] [Pages:97] [Pages No:8-49]



Management of lymph nodes (LN) in medullary thyroid carcinoma (MTC) is an ongoing debate. The aim was to analyze usefulness of sentinel lymph node biopsy (SLNB) of jugulo-carotid regions after methylene blue dye (MBD) mapping for detecting true positive patients in cN0 group of micro-MTCs, providing them one-time lateral neck dissection (LND).


ABSTRACT

Poster Presentations

[Year:2018] [Month:January-April] [Volumn:10 ] [Number:1] [Pages:97] [Pages No:50-95]



It has been well known that thyroid-stimulating hormone (TSH) stimulated the growth or development of thyroid malignancy and higher serum TSH is also associated with thyroid cancer incidence and advanced tumor stage. The purpose of this study was to evaluate the association of preoperative hypothyroidism with the prognosis of papillary thyroid cancer (PTC).


ABSTRACT

Video Presentations

[Year:2018] [Month:January-April] [Volumn:10 ] [Number:1] [Pages:97] [Pages No:96-97]



Needle-assisted endoscopic lateral neck dissection through the bilateral areola approach is a technique of selective neck dissectionfor levels IIA, IIB, III, IV, VB, and VI lymph nodes. This technique has a cosmetic effect on patients with N1b papillary thyroid carcinoma (PTC).


© JAYPEE BROTHERS MEDICAL PUBLISHERS (P) LTD.